Statins aren't a wonder drug | Malcolm Kendrick
This article was corrected on 24 March 2014. It originally said in the eighth paragraph: "Flecainide suppressed dangerous heart arrhythmias, but was pulled from the market for killing thousands of people." This has been amended, as the drug that was pulled from the market was encainide, not flecainide.StatinsDrugsHealthHealth policyMalcolm Kendricktheguardian.com © 2014 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 23, 2014 Category: Science Authors: Malcolm Kendrick Tags: Statins Drugs Health Health policy Society UK news World news The Guardian Comment Comment is free Source Type: news
High potency statins linked to better outcome following heart attack
Treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins, a study concludes after analyzing the data of thousands of patients who suffered heart attacks. The study also found a combination of statins and the drug ezetimibe showed no improved survival rate, although researchers caution this finding needs further testing. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2014 Category: Science Source Type: news
Lower-Intensity Statin Combo Therapy Bests High-Dose Monotherapy for LDL — But So What? (FREE)
By Amy Orciari Herman
Combination therapy with a lower-dose statin plus either a bile acid sequestrant or ezetimibe reduces LDL cholesterol better than high-dose statin monotherapy, but long-term clinical benefits remain uncertain, according to a systematic review in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 11, 2014 Category: Primary Care Source Type: news
All Lots of Liptruzet in U.S. Recalled Over Packaging Defect (FREE)
By Larry Husten
All lots of the combination cholesterol-lowering drug Liptruzet (ezetimibe and atorvastatin) in the U.S. are being recalled because a packaging defect could … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 15, 2014 Category: Primary Care Source Type: news
Large-scale Cholesterol Drug Recall Announced for LiptruzetLarge-scale Cholesterol Drug Recall Announced for Liptruzet
Merck says it is recalling all lots of the ezetimibe/atorvastatin combination drug in four different doses due to a packaging defect. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 14, 2014 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Packaging Defect Leads Merck To Recall All Lots of Liptruzet In US
Merck said today that it was recalling all lots of Liptruzet, its combination of the cholesterol-lowering drugs ezetimibe and atorvastatin, in the US. The company said the recall was due to a packaging defect which could potentially allow air and moisture to affect the quality of the drug, though the company said "the likelihood of the packaging defects decreasing the effectiveness of Liptruzet on a patient’s lipid profile or negatively impacting the safety of the product is remote." To date there have been no adverse events or product complaints reported to the company. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 14, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Evolocumab Beats Zetia for LDL Cholesterol
(MedPage Today) -- The first phase III results for Amgen's investigational anti-PCSK9 human monoclonal antibody -- evolocumab -- indicate the drug performed better than placebo and ezetimibe (Zetia), the company announced Tuesday. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 18, 2013 Category: Cardiology Source Type: news
2014: The Year for Ezetimibe and More?2014: The Year for Ezetimibe and More?
While awaiting the delayed IMPROVE-IT trial, what's a physician to do with patients taking ezetimibe? Dr Walton-Shirley ponders this dilemma and the future of surrogate-end-point trials. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2013 Category: Consumer Health News Tags: Cardiology Blog Source Type: news
Lipid Management with Statins/Ezetimibe Proposed for Chronic Kidney Disease (FREE)
By Joe Elia
The Kidney Disease: Improving Global Outcomes (KDIGO) group is recommending that patients with chronic kidney disease receive lipid management with either statins alone or … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 10, 2013 Category: Primary Care Source Type: news
Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 18, 2013 Category: Consumer Health News Tags: Cholesterol Source Type: news
New Monoclonal Antibody Nabs LDL
(MedPage Today) -- The monoclonal antibody alirocumab, a PCSK9 inhibitor, significantly reduced LDL cholesterol when compared with ezetimibe (Zetia) in a phase III trial, top-line results released by the drug makers showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 17, 2013 Category: Cardiology Source Type: news
PCSK9 Inhibitor Beats Ezetimibe for LDL LoweringPCSK9 Inhibitor Beats Ezetimibe for LDL Lowering
The monoclonal antibody targeting PCSK9 alirocumab significantly reduced LDL-cholesterol levels when compared with ezetimibe in patients with hypercholesterolemia. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Liptruzet: Why Prescribe It?Liptruzet: Why Prescribe It?
Dr. Howard Weintraub discusses the recent approval of Liptruzet, the atorvastatin/ezetimibe combination used to treat elevated LDL-cholesterol levels. Medscape Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2013 Category: Consumer Health News Tags: Cardiology Expert Interview Source Type: news
Liptruzet (ezetimibe and atorvastatin) for the Treatment of Hyperlipidaemia
Liptruzet (ezetimibe and atorvastatin) is a combination drug indicated to reduce elevated low-density lipoprotein (LDL) cholesterol in patients suffering from hyperlipidaemia disorder. (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2013 Category: Pharmaceuticals Source Type: news
Liptruzet (Ezetimibe and Atorvastatin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 17, 2013 Category: Drugs & Pharmacology Source Type: news
